DDInter1351 DDInter1658
Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Osilodrostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zileuton
Osilodrostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Osilodrostat {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Osilodrostat may lead to a major life threatening interaction when taken with Tizanidine
Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib